Actavis has completed its acquisition of Allergan in a cash and equity transaction valued at approximately $70.5 billion. The merger makes Actavis one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015.
The company now has six franchises, including those in eye care, neurosciences/CNS and medical aesthetics/dermatology/plastic surgery, as well as a portfolio of world-renowned brands including BOTOX, RESTASIS, JUVEDERM, NAMENDA XR, LINZESS and Lo Loestrin Fe.
“Our combined company will be built around a customer-focused commitment to partnering with physicians, pharmacists and patients to deliver innovative treatments and enhance access to important therapies around the world,” said Brent Saunders, CEO and president of Actavis.